Unknown

Dataset Information

0

A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a.


ABSTRACT: Background and Aims: Data are limited on the use of pegylated-interferon alpha-2a (peg-IFN?) in Chinese patients with chronic hepatitis B virus (HBV) infection (CHB). We evaluated the effectiveness and safety of peg-IFN? in Chinese patients with hepatitis B envelope antigen-negative CHB in routine clinical practice. Methods: In this prospective, multicenter, observational, non-interventional cohort study, patients were assessed for up to 1 year after peg-IFN? treatment cessation. Treating physicians established the dosing and treatment duration according to Chinese clinical practice. Effectiveness of peg-IFN? treatment was measured by the percentage of: patients with HBV DNA <2000 IU/mL and loss of hepatitis B surface antigen (commonly known as HBsAg); HBV DNA level at end of treatment (EOT), and 6 months and 1 year posttreatment; and time course change in quantitative HBV DNA and HBsAg. Results: At EOT, 6 months posttreatment, and 1 year posttreatment, the percentage of patients with HBV DNA <2000 IU/mL was 90.0%, 81.8%, and 82.2%, and that of patients with HBsAg loss was 6.5%, 9.4%, and 9.5%, respectively. The HBV DNA level decreased from 5.61 log IU/mL at baseline to 2.48 log IU/mL at EOT and 2.67 log IU/mL at 1 year posttreatment. The HBsAg level decreased from 3.08 log IU/mL at baseline to 2.24 log IU/mL at EOT and 2.10 log IU/mL at 1 year posttreatment. The incidence of adverse events was 52.0%. Conclusions: Peg-IFN? has the potential to provide functional cure (HBsAg loss) for CHB and is well tolerated in hepatitis B envelope antigen-negative CHB patients in routine clinical practice in China. Clinical Trial Registration: ClinicalTrials.gov (NCT01730508).

SUBMITTER: Chen X 

PROVIDER: S-EPMC6783682 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a.

Chen Xinyue X   Mao Qianguo Q   Xie Yao Y   Dou Xiaoguang X   Xie Qing Q   Sheng Jifang J   Gao Zhiliang Z   Zhou Xiaoling X   Liu Yingxia Y   Zheng Huanwei H   Zhang Shuqin S   Li Shibo S   Zhu Fusheng F   Xu Yuqin Y   Zhang Mingxiang M   Hu Yaoren Y   Chen Xiaoping X   Huang Yan Y   Ren Hong H   Jia Jidong J  

Journal of clinical and translational hepatology 20190820 3


<b><i>Background and Aims:</i></b> Data are limited on the use of pegylated-interferon alpha-2a (peg-IFNα) in Chinese patients with chronic hepatitis B virus (HBV) infection (CHB). We evaluated the effectiveness and safety of peg-IFNα in Chinese patients with hepatitis B envelope antigen-negative CHB in routine clinical practice. <b><i>Methods:</i></b> In this prospective, multicenter, observational, non-interventional cohort study, patients were assessed for up to 1 year after peg-IFNα treatmen  ...[more]

Similar Datasets

| S-EPMC1942152 | biostudies-literature
| S-EPMC9297582 | biostudies-literature
| S-EPMC9720173 | biostudies-literature
| S-EPMC5405394 | biostudies-literature
| S-EPMC9243604 | biostudies-literature
| S-EPMC9168707 | biostudies-literature
| S-EPMC2716864 | biostudies-other
| S-EPMC9817056 | biostudies-literature
| S-EPMC8627316 | biostudies-literature
| S-EPMC9160736 | biostudies-literature